Quartz·1 min read·medium
Vera Therapeutics stock jumps after the FDA approved its autoimmune kidney drug
✦AI Summary
Vera Therapeutics has seen a stock price increase following FDA approval of its new drug, Trutakna. The medication is designed to treat IgA nephropathy by targeting specific proteins.
Trutakna, priced at $425,000 per year, is the first drug approved in the U.S. that targets both BAFF and APRIL proteins linked to IgA nephropathy
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in